Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045997 | 0.90 | MTNR1A (0.55) | MTNR1AARCREBBPBRD4HTR1A | |
| SCHEMBL7951734 | 0.89 | MTNR1A (0.55) | MTNR1ACREBBPBRD4SMYD3 | |
| SCHEMBL4128722 | 0.89 | MTNR1A (0.53) | MTNR1AARCREBBPBRD4HTR1A | |
| SCHEMBL29593079 | 0.87 | MTNR1A (0.52) | MTNR1AARCREBBPBRD4DRD2 | |
| SCHEMBL22977707 | 0.87 | MTNR1A (0.52) | MTNR1AARCREBBPBRD4DRD2 | |
| SCHEMBL8553887 | 0.87 | MTNR1A (0.52) | MTNR1AARCREBBPBRD4DRD2 | |
| SCHEMBL20870486 | 0.86 | MTNR1A (0.60) | MTNR1AARCREBBPBRD4HTR1A | |
| SCHEMBL22262591 | 0.86 | MTNR1A (0.60) | MTNR1AARCREBBPBRD4HTR1A | |
| SCHEMBL4139663 | 0.86 | MTNR1A (0.60) | MTNR1AARCREBBPBRD4HTR1A | |
| SCHEMBL29659962 | 0.86 | MTNR1A (0.60) | MTNR1AARCREBBPBRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | claimed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | claimed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | claimed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| US-9321730-B2 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-04-26 | — | — | US | disclosed |
| EP-2188259-B1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | UNIV HONG KONG POLYTECHNIC (CN) | 2013-11-06 | — | — | EP | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2009-02-26 | — | — | US | disclosed |
| EP-0198264-A2 | Carbamoyl imidazoles | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054482-A1 | Method of making and administering quinoline derivatives as anti-cancer agents | HCCS, GLS2, NQO1 | MTNR1A 1442/4885AR 4166/4885CREBBP 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.